All In Biotech

Drug Trial Radar · NCT05526716

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,080 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,080

Actual

Start

Sep 23, 2022

Primary completion

Jun 21, 2023

Study completion Jun 21, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with Quadrivalent Influenza Vaccine (QIV) compared with V116 administered sequentially with QIV. The primary hypotheses state that immune responses to V116 and to QIV are non-inferior when administered concomitantly as compared with sequential administration as measured by serotype-specific opsonophagocytic activity (OPA) for V116 and hemagglutination inhibition (HAI) geometric mean titers (GMTs) for QIV, at 30 days postvaccination.

Conditions

  • Pneumonia, Pneumococcal

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • QIVBiological

    Single 0.5 mL IM injection

  • Matching Placebo for V116Biological

    Single 0.5 mL of sterile saline IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
  2. Number of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to ~6 months postvaccination with V116
  4. Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) ResponsesTime frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
  5. GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)Time frame: Day 30

Locations

56 sites in 1 country. Site status is shown where the registry gives one.

  • Central Phoenix Medical Clinic-Synexus Clinical Research US ( Site 0012)

    Phoenix, Arizona

  • Hope Clinical Research, Inc. ( Site 0070)

    Canoga Park, California

  • Paradigm Clinical Research Centers, Inc ( Site 0024)

    La Mesa, California

  • Catalina Research Institute, LLC ( Site 0067)

    Montclair, California

  • WR- PRI, LLC ( Site 0044)

    Newport Beach, California

  • Carbon Health - North Hollywood - NoHo West ( Site 0016)

    North Hollywood, California

  • Valley Clinical Trials, Inc. ( Site 0002)

    Northridge, California

  • Artemis Institute for Clinical Research ( Site 0023)

    San Diego, California

  • WR-MCCR, LLC ( Site 0033)

    San Diego, California

  • California Research Foundation ( Site 0005)

    San Diego, California

  • Diablo Clinical Research, Inc. ( Site 0020)

    Walnut Creek, California

  • Velocity Clinical Research, Hallandale Beach ( Site 0064)

    Hallandale, Florida

  • Indago Research & Health Center, Inc ( Site 0029)

    Hialeah, Florida

  • East Coast Institute for Research, LLC ( Site 0013)

    Jacksonville, Florida

  • Health Awareness ( Site 0034)

    Jupiter, Florida

  • Optimal Research ( Site 0008)

    Melbourne, Florida

  • Suncoast Research Group-Clinical Department ( Site 0062)

    Miami, Florida

  • Suncoast Research Associates ( Site 0041)

    Miami, Florida

  • Alpha Science Research ( Site 0042)

    Miami, Florida

  • Lakes Research ( Site 0063)

    Miami Lakes, Florida

  • Triple O Research Institute, P.A ( Site 0054)

    West Palm Beach, Florida

  • East Coast Institute for Research - Canton ( Site 0004)

    Canton, Georgia

  • Clinical Research Atlanta ( Site 0068)

    Stockbridge, Georgia

  • Synexus Clinical Research US, Inc. ( Site 0072)

    Chicago, Illinois

  • Healthcare Research Network - Chicago ( Site 0014)

    Flossmoor, Illinois

  • Centennial Medical Group ( Site 0035)

    Elkridge, Maryland

  • Healthcare Research Network - St. Louis ( Site 0011)

    St Louis, Missouri

  • Radiant Research ( Site 0073)

    St Louis, Missouri

  • Alivation Research-Primary Care ( Site 0066)

    Lincoln, Nebraska

  • WR-CRCN, LLC ( Site 0018)

    Las Vegas, Nevada

  • Axces Research ( Site 0037)

    Santa Fe, New Mexico

  • Smith Allergy and Asthma Specialists-Certified Research Associates ( Site 0019)

    Cortland, New York

  • Synexus Clinical Research US, Inc - New York ( Site 0053)

    New York, New York

  • Rochester Clinical Research, Inc. ( Site 0055)

    Rochester, New York

  • Meridian Clinical Research, LLC ( Site 0032)

    Vestal, New York

  • Carolina Institute for Clinical Research ( Site 0047)

    Fayetteville, North Carolina

  • M3 Wake Research Associates ( Site 0040)

    Raleigh, North Carolina

  • CTI Clinical Research Center ( Site 0071)

    Cincinnati, Ohio

  • Velocity Clinical Research, Medford ( Site 0060)

    Medford, Oregon

  • Hatboro Medical Associates / CCT Research ( Site 0065)

    Hatboro, Pennsylvania

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.